FAQ
Transparency & Our Commitment to Patients
At La Vida, transparency is foundational. We believe patients deserve complete clarity about what they are receiving, how it is prepared, and why it is priced the way it is.
La Vida was founded in direct response to a troubling industry trend: many stem cell clinics significantly overcharge patients without delivering proportional value in cell quality, quantity, or oversight. While advanced regenerative medicine is complex and costly to deliver properly, it should never require patients to sacrifice their financial security to access care.
Our mission is simple: to provide high-quality, responsibly priced regenerative therapies designed to help relieve pain and injury, support autoimmune and degenerative conditions, and promote long-term health and longevity—without unnecessary markups or inflated promises.
General Laboratory Practices
Passage & Expansion (3)
What is the final harvest passage of the mesenchymal stem cells (MSCs) administered to patients?
The final harvest typically occurs between Passage 3 (P3) and Passage 4 (P4), with most clinical administrations completed at P3.
Do you track population doublings in addition to passage number?
Yes. Population doublings are monitored alongside passage numbers as part of our internal quality and consistency controls.
When it is stated that cells are “passed no more than three times,” what does that mean clinically?
This means the final product administered to the patient is harvested at Passage 3 (P3). Cells are not expanded beyond this stage for treatment.
Cell Count, Dosing & Viability (3)
Do quoted cell numbers refer to live viable cells or total counted cells?
Quoted figures refer to the total cell count at the time of preparation.
How and when are cells counted?
Cell counting begins within 48 hours of umbilical cord or placental acquisition. Final counts are performed during harvesting at Passage 3, using an automated cell counter for accuracy and consistency.
Because our therapies are prepared fresh, timing is coordinated closely with each patient’s presence at the clinic.
What is the typical cell viability at the time of treatment?
Viability typically ranges between 92% and 95% at administration.
Quality Control & Release Testing (3)
Is a Certificate of Analysis (COA) available for the batch used in my treatment?
Yes. Certificates are maintained internally for laboratory oversight. A patient-specific certificate can be issued upon request.
What safety testing is performed, and at what stage?
Standard microbiological testing—including sterility cultures, PCR testing, and endotoxin (LAL) assays—is performed at the final stages of processing in accordance with laboratory protocols.
Are MSC identity markers assessed as part of quality control?
Yes. Identity markers such as CD73, CD90, and CD105 are assessed as part of our standard release criteria.
“Fresh, Never Frozen” Clarification (1)
If cells are not frozen, how is safety ensured when some tests require time to complete?
Safety is ensured through a multi-layered approach that includes GMP-aligned processes, rigorous aseptic techniques, in-process testing, raw material screening, proxy testing, and rapid detection methods. This allows us to deliver fresh cells while maintaining strict safety standards.
Batch Traceability & Documentation (2)
Can patients receive documentation linking their treatment to a specific batch or lot?
Yes. Treatments are fully traceable to specific batches, including harvest date and testing records.
Is this documentation retained and available for patient records?
Absolutely. All records are retained and can be provided upon request.
